Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Single institution outcomes of treatment of severe aplastic anaemia
Autore:
Mollee, P; Woodward, N; Durrant, S; Lockwood, L; Gillett, EA; Morton, J; Rowell, J;
Indirizzi:
Univ Queensland, Royal Brisbane Hosp, Bone Marrow Transplant Unit, Herston, Qld 4029, Australia Univ Queensland Herston Qld Australia 4029 , Herston, Qld 4029, Australia Royal Brisbane Hosp, Haematol Unit, Brisbane, Qld 4029, Australia Royal Brisbane Hosp Brisbane Qld Australia 4029 bane, Qld 4029, Australia Royal Childrens Hosp, Haematol Oncol Unit, Brisbane, Qld, Australia Royal Childrens Hosp Brisbane Qld Australia it, Brisbane, Qld, Australia Queensland Hlth Pathol Serv, Brisbane, Qld, Australia Queensland Hlth Pathol Serv Brisbane Qld Australia sbane, Qld, Australia
Titolo Testata:
INTERNAL MEDICINE JOURNAL
fascicolo: 6, volume: 31, anno: 2001,
pagine: 337 - 342
SICI:
1444-0903(200108)31:6<337:SIOOTO>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; COLONY-STIMULATING FACTOR; TERM FOLLOW-UP; IMMUNOSUPPRESSIVE THERAPY; ANTILYMPHOCYTE GLOBULIN; ANTITHYMOCYTE GLOBULIN; IMPROVED SURVIVAL; MALIGNANT-TUMORS; WORKING PARTY; HOST-DISEASE;
Keywords:
aplastic anaemia; bone marrow transplantation; immunosuppression; unrelated donor transplantation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Durrant, S Univ Queensland, Royal Brisbane Hosp, Bone Marrow Transplant Unit, HerstonRd, Herston, Qld 4029, Australia Univ Queensland Herston Rd Herston Qld Australia 4029 Australia
Citazione:
P. Mollee et al., "Single institution outcomes of treatment of severe aplastic anaemia", INTERN M J, 31(6), 2001, pp. 337-342

Abstract

Background: In severe aplastic anaemia, the treatment of choice for young patients with a human leucocyte antigen-matched sibling is now established as allogeneic bone marrow transplantation (BMT). In older patients and in those without a matched sibling donor, immunosuppressive therapy is the usual first option. 'Alternative' marrow donors are emerging as an option for those without a matched sibling donor. Aims: To review 10 years of local experience in treating severe aplastic anaemia with BMT and immunosuppressive therapy with emphasis on long-term outcomes. Methods: A retrospective analysis was performed of all patients with severe aplastic anaemia presenting to the Royal Brisbane and Royal Children's Hos- pitals between 1989 and 1999. Data were abstracted regarding patient demographics, pretreatment characteristics and outcome measures, including response rates, overall survival and long-term complications. Results: Twenty-seven consecutive patients were identified, 12 treated with immunosuppression alone and 15 with BMT. In these two groups, transfusionindependence was attained in 25% and 100%, respectively, with overall survival being 36% and 100%, respectively. Those treated with immunosuppressionwere significantly older (median 41.5 versus 22 years, P = 0.008). Long-term survivors of either treatment had extremely low morbidity. Three patients carried pregnancies to term post-transplant. Three patients received alternative donor BMT with correspondingly excellent survival. Conclusions: Patients treated with allogeneic BMT for severe aplastic anaemia enjoyed extremely good long-term survival and minimal morbidity. Patients treated with immunosuppressive therapy had a poorer outcome reflecting their older age and different usage of therapies over the past decade. Optimal treatment strategies for severe aplastic anaemia remain to be determined.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 03:23:16